Meta-Analysis: Cannabinoids Provide Small Pain Relief for Chronic Neuropathic Pain
Across 11 randomized trials with 1,219 patients, selective cannabinoids provided a statistically significant but clinically small reduction in neuropathic pain scores, with improvements in quality of life and sleep.
Quick Facts
What This Study Found
This systematic review and meta-analysis addressed the conflicting recommendations from pain societies about cannabinoids for neuropathic pain.
Across 11 RCTs including 1,219 patients, selective cannabinoids (dronabinol, nabilone, nabiximols) produced a statistically significant reduction in pain scores compared to placebo or conventional treatment: -0.65 points on a 0-10 scale. While statistically significant, this was considered clinically small.
Beyond pain scores, cannabinoid use was associated with improvements in quality of life and sleep, and no major adverse effects were reported. The evidence was graded as moderate quality with a weak recommendation using the GRADE approach.
The heterogeneity across studies was high (I-squared = 60%), reflecting variability in the etiology of neuropathic pain, types and doses of cannabinoids used, and study quality.
Key Numbers
11 RCTs, 1,219 patients (614 cannabinoid, 605 comparator). Pain reduction: -0.65 points on 0-10 NRS (95% CI -1.06 to -0.23, p=0.002). I-squared: 60%. GRADE: weak recommendation, moderate-quality evidence.
How They Did This
Systematic review and meta-analysis of RCTs comparing selective cannabinoids (dronabinol, nabilone, nabiximols) with conventional treatments or placebo for chronic neuropathic pain. Searched MEDLINE, EMBASE, and other databases through March 2016. GRADE approach used for evidence certainty.
Why This Research Matters
National and international pain societies have given contradictory recommendations about cannabinoids for neuropathic pain. This meta-analysis provides a quantitative answer: there is a real but small benefit, supporting cannabinoids as an option but not a first-line treatment.
The Bigger Picture
A 0.65-point reduction on a 10-point pain scale may seem small, but for patients with treatment-resistant neuropathic pain who have failed conventional therapies, any reduction can be meaningful. Combined with improvements in sleep and quality of life, cannabinoids fill a niche for patients without other options.
What This Study Doesn't Tell Us
High heterogeneity across studies. The effect size is small and may not be clinically meaningful for all patients. Studies varied in cannabinoid type, dose, and neuropathic pain etiology. The search ended March 2016 and newer trials are not included.
Questions This Raises
- ?Are specific cannabinoid formulations more effective for particular types of neuropathic pain?
- ?Would higher doses produce larger effects or only more side effects?
- ?Could cannabinoids be more effective as adjuncts to other pain medications rather than as standalone treatments?
Trust & Context
- Key Stat:
- -0.65 point pain reduction on a 0-10 scale across 1,219 patients
- Evidence Grade:
- Meta-analysis of 11 RCTs with GRADE assessment. Strong methodology with moderate-quality underlying evidence.
- Study Age:
- Published in 2017, searching through March 2016.
- Original Title:
- Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis.
- Published In:
- Anesthesia and analgesia, 125(5), 1638-1652 (2017)
- Authors:
- Meng, Howard, Johnston, Bradley, Englesakis, Marina(2), Moulin, Dwight E, Bhatia, Anuj
- Database ID:
- RTHC-01455
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Do cannabinoids help with nerve pain?
This meta-analysis found a statistically significant but clinically small reduction in neuropathic pain scores with cannabinoids. The average reduction was 0.65 points on a 10-point scale, with additional benefits for sleep and quality of life.
Should cannabinoids be first-line treatment for nerve pain?
No. The GRADE assessment gave a "weak recommendation" based on moderate-quality evidence. Cannabinoids appear to be an option for patients who have not responded to conventional treatments, not a first-line therapy.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01455APA
Meng, Howard; Johnston, Bradley; Englesakis, Marina; Moulin, Dwight E; Bhatia, Anuj. (2017). Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis.. Anesthesia and analgesia, 125(5), 1638-1652. https://doi.org/10.1213/ANE.0000000000002110
MLA
Meng, Howard, et al. "Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis.." Anesthesia and analgesia, 2017. https://doi.org/10.1213/ANE.0000000000002110
RethinkTHC
RethinkTHC Research Database. "Selective Cannabinoids for Chronic Neuropathic Pain: A Syste..." RTHC-01455. Retrieved from https://rethinkthc.com/research/meng-2017-selective-cannabinoids-for-chronic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.